TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30852966

Group type: EXPERIMENTAL
Intervention: Elevated serum netrin-1 levels
Number of subjects: 3346

Group type: COMPARATOR
Intervention: Baseline National Institutes of Health Stroke Scale score and other potential confounders
Number of subjects: 3346
Study: 30853049

Group type: EXPERIMENTAL
Intervention: Computer Decision Support System (CDSS) for OSA detection
Number of subjects: 2535
Study: 30853195

Group type: EXPERIMENTAL
Intervention: Pediatric weight management programs
Number of subjects: 6454

Group type: EXPERIMENTAL
Intervention: Older age (≥12 years), greater severity of obesity, and Hispanic race/ethnicity
Number of subjects: 6454

Group type: EXPERIMENTAL
Intervention: 5-percentage point decrease in %BMIp95
Number of subjects: 6454
Study: 30853233

Group type: EXPERIMENTAL
Intervention: Peak systolic blood pressure
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Peak mean arterial pressure
Number of subjects: 793
Study: 30853642

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in never injectors
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID not on OAT
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID on OAT
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in ongoing drug users (with or without OAT)
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in ongoing drug users
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in never injectors (per protocol analysis)
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID not on OAT (per protocol analysis)
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Interferon-free DAA treatment in PWID on OAT (per protocol analysis)
Number of subjects: 1752
Study: 30854456

Group type: EXPERIMENTAL
Intervention: Spectroscopic MRI (sMRI) integrated with standard imaging for radiation therapy planning
Number of subjects: 18
Study: 30855220

Group type: EXPERIMENTAL
Intervention: Uterus transplant (UTx)
Number of subjects: 19
Study: 30855519

Group type: EXPERIMENTAL
Intervention: WAGR subjects with BDNF gene deletion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heterozygous Bdnf knockout rats
Number of subjects: 0
Study: 30855742

Group type: EXPERIMENTAL
Intervention: EVD survivors
Number of subjects: 966
Study: 30857495

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 386
Study: 30857528

Group type: EXPERIMENTAL
Intervention: Sensation Seeking Scale for Young Children
Number of subjects: 423
Study: 30857532

Group type: EXPERIMENTAL
Intervention: Post-procedural glycemic variability (mean daily δ blood glucose during the first 2 days after TAVI, median value 4.3 mmol/l)
Number of subjects: 160
Study: 30857780

Group type: EXPERIMENTAL
Intervention: Retreatment with a different antiviral regimen
Number of subjects: 0
Study: 30857849

Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Children with CHD (complex CHD types)
Number of subjects: 834
Study: 30857956

Group type: EXPERIMENTAL
Intervention: Pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 57
Study: 30858085

Group type: EXPERIMENTAL
Intervention: CRLX101 with standard neoadjuvant chemoradiotherapy (CRT)
Number of subjects: 32
Study: 30858218

Group type: EXPERIMENTAL
Intervention: DSM265 at 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30858739

Group type: EXPERIMENTAL
Intervention: ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin (pegIFN-α2a/RBV) for 48 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Safety and tolerability of the regimen
Number of subjects: 32
Study: 30858826

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30858899

Group type: EXPERIMENTAL
Intervention: Psychoeducational workshop (two-day workshop with short conferences, group sharing, and role playing activities)
Number of subjects: 7
Study: 30858985

Group type: EXPERIMENTAL
Intervention: Fish protein supplementation (5.2 g daily for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30858986

Group type: EXPERIMENTAL
Intervention: Wireless monitoring system
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study: 30859371

Group type: EXPERIMENTAL
Intervention: Point-of-care measurement of purines (adenosine, inosine, hypoxanthine) using SMARTCap biosensor in stroke patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Point-of-care measurement of purines (adenosine, inosine, hypoxanthine) using SMARTCap biosensor in stroke patients after 24 hours
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Correlation of purine levels with volume of affected brain tissue
Number of subjects: 128
Study: 30859424

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) sampling using dual tracer method
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single agent blue dye injection
Number of subjects: 10
Study: 30859504

Group type: EXPERIMENTAL
Intervention: Personalized trials of BP medications
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thiazides
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system-blocking agents
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of thiazide and beta-blocker
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Any of three classes of BP medications
Number of subjects: 10
Study: 30859546

Group type: COMPARATOR
Intervention: Women without avulsions
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Women with avulsions
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Preoperative anterior compartment stage ≥III
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: High preoperative symptom score
Number of subjects: 189
Study: 30860013

Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction (PCR) testing
Number of subjects: 0
Study: 30860484

Group type: EXPERIMENTAL
Intervention: Tablet app for the Simplified Gestational Age Score (T-SGAS) used by auxiliary nurse midwives to estimate GA status of newborns.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-SGAS app
Number of subjects: 0
Study: 30860496

Group type: EXPERIMENTAL
Intervention: Defined composition CD19 CAR T cells
Number of subjects: 43
Study: 30860858

Group type: EXPERIMENTAL
Intervention: Asthma controller medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute healthcare use
Number of subjects: 0
Study: 30860945

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once per day plus capecitabine 750 mg/m²
Number of subjects: 49
Study: 30861475

Group type: EXPERIMENTAL
Intervention: Better mental health (higher MHI-5 scores)
Number of subjects: 668

Group type: COMPARATOR
Intervention: More mental health problems (lower MHI-5 scores)
Number of subjects: 668
Study: 30862609

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy (platinum/pemetrexed)
Number of subjects: 1
Study: 30862646

Group type: EXPERIMENTAL
Intervention: Isatuximab plus pomalidomide/dexamethasone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isatuximab (5 mg/kg, 10 mg/kg, or 20 mg/kg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isatuximab (10 mg/kg)
Number of subjects: 45
Study: 30862645

Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 82
Study: 30862650

Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled insulin pen caps
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Most adherent tertile
Number of subjects: 75
Study: 30863020

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (educational program for psychiatrists, collaborative care program for patients and relatives, reminder system using a medication reminder application)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 400
Study: 30863043

Group type: EXPERIMENTAL
Intervention: COPD patients during acute exacerbation
Number of subjects: 181
Study: 30863141

Group type: EXPERIMENTAL
Intervention: Methoxyflurane (up to 6 mL)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Overall treatment effect of methoxyflurane vs placebo
Number of subjects: 96
Study: 30863297

Group type: EXPERIMENTAL
Intervention: intermittent theta-burst stimulation (iTBS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: continuous TBS (cTBS)
Number of subjects: 22
Study: 30863450

Group type: EXPERIMENTAL
Intervention: UC-MSC + PE
Number of subjects: 110

Group type: COMPARATOR
Intervention: Single treatment (Control)
Number of subjects: 110
Study: 30863936

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 1140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1140
Study: 30864114

Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 7
Study: 30864887

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30865002

Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Index-3 score higher than seven points
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lack of PONV prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative administration of opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study: 30865003

Group type: EXPERIMENTAL
Intervention: Intra-operative FiO2 of 80%
Number of subjects: 5056

Group type: COMPARATOR
Intervention: Intra-operative FiO2 of 30%
Number of subjects: 5056
Study: 30865059

Group type: EXPERIMENTAL
Intervention: Psychostimulants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compensation strategies
Number of subjects: 0
Study: 30865223

Group type: EXPERIMENTAL
Intervention: Molecular-based recommended therapies (MBRT)
Number of subjects: 2579
Study: 30865367

Group type: EXPERIMENTAL
Intervention: Heart failure medications (including ACE-Is/ARBs, β-blockers, MRAs, digoxin, ivabradine, diuretics)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: N-terminal pro B-type natriuretic peptide levels
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Prevalence of atrial fibrillation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Prevalence of anaemia
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Prevalence of HFmrEF
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Prevalence of HFpEF
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 123
Study: 30865549

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 118
Study: 30865772

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-guided lumbar epidural needle insertion
Number of subjects: 22
Study: 30865842

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30866001

Group type: EXPERIMENTAL
Intervention: Patient-facing family health history (FHH)-based risk assessment platform
Number of subjects: 2514
Study: 30866104

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 19
Study: 30866621

Group type: EXPERIMENTAL
Intervention: Graded exercise integrated with education
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 44
Study: 30866657

Group type: EXPERIMENTAL
Intervention: nHDL <100 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: nHDL 100-129 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: nHDL ≥130 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: LDL <70 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: LDL 70-99 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: LDL ≥100 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Triglyceride <84 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Triglyceride 84-149 mg/dL
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Triglyceride ≥150 mg/dL
Number of subjects: 1843
Study: 30866676

Group type: EXPERIMENTAL
Intervention: Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance model
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-ceding site
Number of subjects: 13

Group type: COMPARATOR
Intervention: Published averages for academic medical centers
Number of subjects: 13

Group type: COMPARATOR
Intervention: Published averages for enrollment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Stakeholder satisfaction with reliance experience
Number of subjects: 13
Study: 30866879

Group type: EXPERIMENTAL
Intervention: ProAsk mHealth intervention
Number of subjects: 66
Study: 30866942

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 187
Study: 30866994

Group type: EXPERIMENTAL
Intervention: Use of a stabilizing connecting device for ultrasound transducer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coagulated blood from the patient as an alternative for ultrasound gel
Number of subjects: 0
Study: 30867154

Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I (hs-cTnI) assay
Number of subjects: 20000
Study: 30867337

Group type: EXPERIMENTAL
Intervention: Reduced REM sleep
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Lowest REM quartile group
Number of subjects: 1234

Group type: EXPERIMENTAL
Intervention: Highest REM quartile group
Number of subjects: 1234
Study: 30867794

Group type: EXPERIMENTAL
Intervention: Intra-tumor AvidinOX with low systemic dose biotinylated cetuximab (bCet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-tumor AvidinOX with low systemic dose biotinylated cetuximab (bCet) plus low dose cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low systemic dose biotinylated cetuximab (bCet) without AvidinOX
Number of subjects: 0
Study: 30867935

Group type: EXPERIMENTAL
Intervention: Safe Childbirth Checklist (SCC) program implemented in 19 intervention facilities with monthly supportive supervision and supply of drugs and equipment.
Number of subjects: 77

Group type: COMPARATOR
Intervention: Routine care provided in 15 comparison facilities without the SCC program.
Number of subjects: 77
Study: 30868245

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) 300/120 mg for 8 weeks
Number of subjects: 899
Study: 30868419

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.07%
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nepafenac 0.3%
Number of subjects: 49
Study: 30868475

Group type: EXPERIMENTAL
Intervention: Usual care plus PEMF therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care plus sham
Number of subjects: 42
Study: 30868550

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 660

Group type: COMPARATOR
Intervention: Tumor Necrosis Factor Inhibitors (TNFis)
Number of subjects: 660
Study: 30868758

Group type: EXPERIMENTAL
Intervention: Microarray-based gene expression data analysis for assessing rejection in kidney transplant biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated kidney transplant biopsy report generation
Number of subjects: 0
Study: 30869114

Group type: EXPERIMENTAL
Intervention: Early childhood protein intake (mean 58.3 g/d)
Number of subjects: 1165

Group type: EXPERIMENTAL
Intervention: Early childhood protein intake
Number of subjects: 1165
Study: 30869127

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine treatment
Number of subjects: 47
Study: 30870275

Group type: EXPERIMENTAL
Intervention: Etonogestrel implants
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: CYP3A7*1C variant
Number of subjects: 350
Study: 30871357

Group type: EXPERIMENTAL
Intervention: Prior CABG patients (n=1101)
Number of subjects: 3486

Group type: COMPARATOR
Intervention: No prior CABG patients (n=2317)
Number of subjects: 3486
Study: 30871358

Group type: EXPERIMENTAL
Intervention: Transfemoral TAVI
Number of subjects: 10982
Study: 30871413

Group type: EXPERIMENTAL
Intervention: Training on PrEP service delivery using a two-day case-based interactive curriculum
Number of subjects: 716
Study: 30871484

Group type: EXPERIMENTAL
Intervention: Early initiation group (EIG)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Delayed initiation group (DIG)
Number of subjects: 444
Study: 30871493

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg Q2W) followed by nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W) after a 3-cycle run-in phase.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nivolumab (240 mg Q2W) only for patients not escalated to ipilimumab.
Number of subjects: 75
Study: 30871507

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: BIS monitoring with opioid, propofol, and nitrous oxide
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Sevoflurane concentration with BIS monitoring
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 2833

Group type: EXPERIMENTAL
Intervention: Rapid onset OCR
Number of subjects: 2833
Study: 30871693

Group type: EXPERIMENTAL
Intervention: In vivo contrast-enhanced CT angiography
Number of subjects: 0
Study: 30871768

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 30871960

Group type: EXPERIMENTAL
Intervention: CBT-I (n = 26)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I + Med (n = 25)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I (n = 54)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I + Med (n = 54)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I (short sleep duration)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I + Med (short sleep duration)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I (normal sleep duration)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CBT-I + Med (normal sleep duration)
Number of subjects: 159
Study: 30872042

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) measured at index visit and at a 12-month interval
Number of subjects: 169
Study: 30872087

Group type: EXPERIMENTAL
Intervention: EUS-FNB
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unroofing biopsy
Number of subjects: 39
Study: 30872388

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with mild hepatic impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with moderate hepatic impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg oral dose) in patients with normal hepatic function
Number of subjects: 0

Group type: COMPARATOR
Intervention: Population PK analysis of osimertinib
Number of subjects: 0
Study: 30872988

Group type: EXPERIMENTAL
Intervention: Janssen Autism Knowledge Engine (JAKE)
Number of subjects: 0
Study: 30873017

Group type: EXPERIMENTAL
Intervention: Stable whole-limb machine-based resistance training (S-MRT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Instability free-weight resistance training (I-FRT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Stable machine-based adductor/abductor resistance training (S-MRT)
Number of subjects: 68
Study: 30873106

Group type: EXPERIMENTAL
Intervention: Double Inversion Recovery MRI
Number of subjects: 0
Study: 30873285

Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, emails, and mailed incentives (4 HV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2 home visits, emails, and mailed incentives (2 HV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: General health emails (control)
Number of subjects: 44
Study: 30873290

Group type: EXPERIMENTAL
Intervention: Milk powder supplemented with calcium and vitamin D and periodontal therapy (PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment and consumption of milk fortified with calcium-vitamin D
Number of subjects: 0
Study: 30873378

Group type: EXPERIMENTAL
Intervention: Apixaban for primary prevention of VTE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study: 30873623

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) ± antiplatelet (AP) therapy
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Non-VKA oral anticoagulant (NOAC) ± AP
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Antiplatelet (AP) only
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: No antithrombotic treatment
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 4162
Study: 30873942

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 1117
Study: 30875094

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg + Osimertinib 80 mg single dose on days 1 and 39 and Osimertinib 80 mg once daily from days 4 to 41
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg + Osimertinib 80 mg at steady state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fexofenadine alone
Number of subjects: 24
Study: 30876390

Group type: EXPERIMENTAL
Intervention: ACC/AHA 2013 cholesterol guidelines
Number of subjects: 4378

Group type: COMPARATOR
Intervention: NCEP-ATP recommendations
Number of subjects: 4378
Study: 30876442

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin) at Maximum Tolerated Dose (MTD) of 59.92Gy/2.14Gy/28f
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy
Number of subjects: 53